TOP HEADLINES

Featured Story

Amarantus scores a small victory in the advance of its Alzheimer's Dx test

Alzheimer's watchers are left for the moment focusing on small victories. Amarantus Bioscience Holdings recently accomplished one, completing enrollment in a planned study of 72 patients to assess the feasibility of LymPro, its Alzheimer's blood diagnostic test.

Belgium's VolitionRx touts positive early results for noninvasive colon cancer Dx

VolitionRx said it will pursue a CE mark application later in 2014 or early 2015, based, in part on initial positive results from a major study involving its noninvasive colorectal cancer diagnostic test panel.

Pittsburgh outfit launches blood Dx to measure pediatric transplant rejection risk

The FDA has signed-off on a new blood test that can help predict whether transplanted livers or intestines will be rejected after being implanted in children.

Gene-sequencing leukemia research could boost Dx and treatment for kids with a rare disease subtype

St. Jude Children's Research Hospital and colleagues from around the country used next-generation sequencing in a study that could upend how a high-risk leukemia subtype is diagnosed and treated in children and adolescents.

BG Medicine slashes staff before launching automated version of heart failure test

BG Medicine is laying off more than half of its workforce as it gears up for the commercial launch of automated versions of its test for chronic heart failure.

MORE NEWS

From Our Sister Sites

FierceBiotech

Sanofi has stepped up with a $45 million down payment on a potential $200 million early-stage deal to develop new drugs for heart muscle disease. The pharma giant inked one if its rare small-biotech...

FierceBiotech

Just a few days after Auxilium Pharmaceuticals put out the word that pressure on the sales side was forcing a restructuring and the elimination of about 200 jobs, Endo has come along with a proposal to buy out the company for about $2.2 billion worth of cash and stock.